Cytek Biosciences, Inc. (CTKB)
After hours:
| Previous close | 5.63 |
| Open | 5.69 |
| Bid | 5.74 x 200 |
| Ask | 5.79 x 100 |
| Day's range | 5.59 - 5.76 |
| 52-week range | 3.80 - 12.31 |
| Volume | |
| Avg. volume | 692,025 |
| Market cap | 753.546M |
| Beta (5Y monthly) | 1.37 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.09 |
| Earnings date | 06 May 2024 - 10 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 10.00 |
ZacksCytek Biosciences (CTKB) Is Considered a Good Investment by Brokers: Is That True?
The average brokerage recommendation (ABR) for Cytek Biosciences (CTKB) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
ZacksCytek Biosciences (CTKB) Loses -7.27% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Cytek Biosciences (CTKB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
ZacksWall Street Analysts Believe Cytek Biosciences (CTKB) Could Rally 47.61%: Here's is How to Trade
The consensus price target hints at a 47.6% upside potential for Cytek Biosciences (CTKB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
